Kneat.com (KSI) Planet MicroCap Showcase: VEGAS 2025 summary

Market position and customer satisfaction

• Recognized as a market leader in life sciences validation software, with high customer retention and satisfaction rates at 97%.

• Achieved 100% renewal intent among surveyed customers, driving strong organic growth and expanding customer base.

• Net revenue retention reached 151%, reflecting significant expansion within existing accounts.

• Most of the largest global pharmaceutical companies are customers, with deep penetration in key accounts.

• 87% compound annual growth rate in annual recurring revenue over the past four years.

Product capabilities and differentiation

• Offers a no-code, highly configurable platform that digitizes and streamlines validation processes for life sciences.

• Captures real-time, granular validation data, enabling faster, more collaborative, and transparent workflows.

• Platform supports a wide range of validation needs, from equipment to facilities and document management.

• Competes primarily with one legacy provider and Veeva, with a focus on configurability and depth of offering.

• Difficult for customers to switch once implemented due to deep integration and user satisfaction.

Financial performance and growth outlook

• Ended last year with approximately CAD 50 million in revenue and gross margins rising to 75%.

• Operating expenses are growing much slower than gross profit, supporting a trajectory toward profitability.

• EPS was cut by more than half, and operating expenses grew 15% versus nearly 60% gross profit growth.

• Revenue growth is primarily driven by customer expansion and upsell, not price increases.

• TAM for validation in life sciences is estimated at $2 billion, with potential to expand to $7 billion in broader quality management.